- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | H.C. Wainwright reiterates Orchestra BioMed stock rating on trial enrollment | 1 | Investing.com | ||
| Do | Orchestra BioMed Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| Mi | OBIO marks $704m funding milestone for Canadian health tech ventures | 2 | Pharmaceutical Technology | ||
| 16.09. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026 | 3 | GlobeNewswire (USA) | ||
| ORCHESTRA BIOMED Aktie jetzt für 0€ handeln | |||||
| 15.09. | Orchestra BioMed receives $6.1m milestone from Vivasure deal | 1 | Investing.com | ||
| 15.09. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics | 304 | GlobeNewswire (Europe) | Payment follows approximately $5 million received in January 2026, bringing total cash proceeds received to approximately $11 millionCompany remains eligible for up to approximately $10 million in... ► Artikel lesen | |
| 10.09. | BTIG upgrades Orchestra BioMed stock rating on trial progress | 1 | Investing.com | ||
| 10.09. | BTIG stuft Orchestra BioMed Aktie hoch: Fortschritte bei klinischer Studie überzeugen | 2 | Investing.com Deutsch | ||
| 08.09. | Orchestra BioMed Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 19.08. | Biotech Stocks At 52-Week Highs - Amylyx Pharmaceuticals +63% With Phase 3 Data, Vogenx +25%, Orchestra BioMed +19%, AtriCure, Charles River Laboratories | 1.252 | AFX News | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 18, 2026, primarily driven by positive quarterly reports.Amylyx Pharmaceuticals Inc. (AMLX)Amylyx Pharmaceuticals... ► Artikel lesen | |
| 10.08. | Orchestra BioMed Holdings, Inc. Q2 Sales Decline | 1 | RTTNews | ||
| 10.08. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates | 279 | GlobeNewswire (Europe) | The BACKBEAT global pivotal trial ("BACKBEAT Trial"), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary... ► Artikel lesen | |
| 29.06. | Aufnahme in Russell Indizes treibt Aktie von Orchestra BioMed an | 2 | Investing.com Deutsch | ||
| 29.06. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Joins Russell 3000 and Russell 2000 Indexes | 304 | GlobeNewswire (Europe) | NEW HOPE, Pa., June 29, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to... ► Artikel lesen | |
| 23.06. | Orchestra BioMed Holdings, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 02.06. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 13.05. | Orchestra BioMed targets completed BACKBEAT enrollment by end of Q3 2026 | 8 | MassDevice | ||
| 12.05. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates | 584 | GlobeNewswire (Europe) | Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial ("BACKBEAT Trial") by the end of Q3 2026Medtronic (NYSE: MDT) and Orchestra BioMed intend to pursue late-breaking... ► Artikel lesen | |
| 12.05. | Orchestra BioMed Holdings, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 12.05. | Orchestra BioMed targets Q3 2026 enrollment for hypertension trial | 3 | Investing.com |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| RECURSION PHARMACEUTICALS | 4,790 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program | Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,270 | 0,00 % | Astrazeneca investiert 2 Mrd USD in Summit Therapeutics - Kooperation vertieft | DJ Astrazeneca investiert 2 Mrd USD in Summit Therapeutics - Kooperation vertieft
Von Elias Schisgall
DOW JONES--Astrazeneca investiert im Rahmen einer erweiterten Partnerschaft 2 Milliarden... ► Artikel lesen | |
| QIAGEN | 40,185 | +5,80 % | Microsoft, Newron, Pyrum, Qiagen, Börse München - das 4investors.de-Weekend | Was hat Anleger am Wochenende bewegt? Hier sind die 4investors.de-Berichte vom Wochenende mit spannenden Aktien-Stories zu Microsoft, Newron, Pyrum, Qiagen sowie der Börsenpresseschau der Börse München.... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 284,03 | 0,00 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| MBX BIOSCIENCES | 58,54 | +0,05 % | Guggenheim raises MBX Biosciences price target to $150 on obesity drug potential | ||
| BRAVEHEART BIO | 21,350 | +0,38 % | Stifel reiterates Buy on Braveheart Bio stock, $45 target | ||
| AMYLYX PHARMACEUTICALS | 27,780 | 0,00 % | Amylyx Pharma Q2 2026 Earnings Call Transcript | ||
| ERASCA | 14,740 | 0,00 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| NAUTILUS BIOTECHNOLOGY | 1,865 | 0,00 % | Roth/MKM initiates Nautilus Biotechnology stock with buy rating | ||
| EDGEWISE THERAPEUTICS | 40,350 | 0,00 % | Edgewise Therapeutics Reports Second Quarter 2026 Financial Results | - Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) -
- ... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 45,470 | -3,19 % | This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday | ||
| MODERNA | 180,90 | +7,28 % | Moderna-Aktie springt über 200 US$ - wie weit noch? | Die Moderna-Aktie meldet sich mit einem gewaltigen Kurssprung zurück. Innerhalb einer Woche steigt der Biotechnologietitel um über +24% auf zeitweise über 202,00 US$ und durchbricht damit einen mehrjährigen... ► Artikel lesen | |
| ARRIVENT BIOPHARMA | 28,460 | +0,67 % | ArriVent BioPharma, Inc.: ArriVent BioPharma Reports Second Quarter 2026 Financial Results | Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026ARR-217, a CDH17 targeted ADC for gastrointestinal malignancies, advanced to... ► Artikel lesen | |
| ABSCI | 11,530 | 0,00 % | Guggenheim reiterates Absci stock rating on endometriosis trial delay | ||
| DYNE THERAPEUTICS | 15,450 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) | - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus... ► Artikel lesen |
Das Unternehmen ORCHESTRA BIOMED HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,095 (+1,59 %) liegt der Kurs bei 6,060 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ORCHESTRA BIOMED HOLDINGS INC finden Sie auf Wallstreet Online.